Gyre Therapeutics Financial Statements
NASDAQ: GYREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Gyre Therapeutics revenue and earnings
In fiscal 2025, Gyre Therapeutics generated $116.6 million in revenue, up 10.2% from fiscal 2024. Net income was $9.9 million (-44.8% year over year), for a net margin of 8.5% versus a median of -75.3% in the prior 5 years. Gross margin was 95.4% (down from 96.3%) and operating margin 9.9%.
Diluted earnings per share came in at $0.02, down from $0.05. Over the last 5 fiscal years, GYRE's revenue has grown at a 41.0% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Gyre Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 116.59M | 105.76M | 113.45M | 102.29M | 7.34M | 20.95M | — | 6.00K | 1.02M | — |
| Revenue growth (YoY) | +10.24% | -6.78% | +10.91% | +1293.98% | -64.97% | — | — | -99.41% | — | — |
| Cost of Revenue | 5.42M | 3.88M | 4.64M | 4.79M | — | — | — | — | — | — |
| Gross Profit | 111.17M | 101.87M | 108.81M | 97.50M | — | — | — | — | — | — |
| Operating Expenses | 105.10M | 89.59M | 176.04M | 88.29M | 95.23M | 78.32M | 57.28M | 33.83M | 22.84M | 20.82M |
| Research & Development | 13.70M | 12.02M | 13.78M | 16.69M | 68.89M | 52.98M | 43.86M | 21.47M | 12.85M | 11.55M |
| Selling, General & Admin | 85.98M | 73.62M | 75.82M | 71.61M | — | — | — | — | — | — |
| Operating Income | 11.49M | 16.16M | -67.23M | 9.20M | -87.89M | -57.37M | -57.28M | -33.82M | -21.82M | -20.42M |
| Other Income (Expense) | -1.50M | -1.66M | -1.52M | 857.00K | -78.00K | -91.00K | -39.00K | 1.65M | -1.00K | 86.00K |
| Pretax Income | 14.44M | 23.22M | -76.97M | 9.41M | -87.93M | — | — | — | — | — |
| Income Tax | 4.56M | 5.32M | 8.52M | 5.10M | — | — | — | — | — | — |
| Net Income | 9.88M | 17.90M | -85.48M | 4.31M | -87.93M | -56.24M | -55.18M | -30.05M | -21.56M | -16.95M |
| Net Income growth (YoY) | -44.80% | — | -2081.46% | — | — | — | — | — | — | — |
| EPS (Basic) | 0.06 | 0.14 | -1.41 | 0.04 | -2.87 | -2.93 | -4.60 | -2.68 | -7.45 | -21.75 |
| EPS (Diluted) | 0.02 | 0.05 | -1.41 | 0.03 | -2.87 | -2.93 | -4.60 | -2.68 | -7.45 | -21.75 |
| Shares Outstanding (Basic) | 89.34M | 85.09M | 65.83M | 63.59M | 30.64M | 19.18M | 12.00M | 11.21M | 3.42M | 779.17K |
| Shares Outstanding (Diluted) | 103.18M | 102.29M | 65.83M | 75.69M | 30.64M | 19.18M | 12.00M | 11.21M | 3.42M | 779.17K |
| EBITDA | 13.97M | 17.71M | -66.16M | 10.29M | -87.60M | -57.23M | -57.13M | -33.67M | -21.65M | -20.03M |
| Gross Margin | 95.35% | 96.33% | 95.91% | 95.31% | — | — | — | — | — | — |
| Operating Margin | 9.85% | 15.28% | -59.26% | 9.00% | -1197.79% | -273.87% | — | -563700.00% | -2143.61% | — |
| Net Margin | 8.47% | 16.92% | -75.35% | 4.22% | -1198.32% | -268.48% | — | -500916.67% | -2117.98% | — |
This table shows 10 annual periods of Gyre Therapeutics's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow GYRE's reporting calendar. What is a income statement?